| Niraparib Plus Anlotinib for Recurrent Ovarian Cancer (NCT05311579) | Lei Li | 2022-03-27 |
| Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma (NCT05030077) | Tianjin Medical University Second Hospital | 2021-10-01 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer (NCT04807166) | Wenjun Cheng | 2021-08-24 |
| Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer (NCT04803851) | Peking Union Medical College Hospital | 2021-05-12 |
| Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC (NCT05400070) | Tang-Du Hospital | 2021-03-01 |
| SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer (NCT04797507) | Peking Union Medical College Hospital | 2021-03-01 |
| Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (NCT04566952) | Xiaoxiang Chen | 2020-10-28 |
| Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (NCT04271813) | Shanghai Changzheng Hospital | 2020-06-01 |
| Preoperative IMRT With Anlotinib and Penpulimab for Localized Sarcoma （SPARE-01） (NCT05167994) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2020-05-01 |
| Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence (NCT04213118) | First Affiliated Hospital Xi'an Jiaotong University | 2020-04-23 |
| Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study (NCT04313660) | Xiaorong Dong | 2020-04-01 |
| Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) (NCT04278222) | Shanghai Changzheng Hospital | 2020-02-10 |
| A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer (NCT04757779) | First People's Hospital of Hangzhou | 2019-12-30 |
| Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC (NCT04116918) | Baodong Qin | 2019-09-01 |
| Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer (NCT04684017) | Shanghai Chest Hospital | 2019-05-01 |
| Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma (NCT03936452) | Sun Yat-sen University | 2019-04-28 |
| Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer (NCT03589950) | The First People's Hospital of Lianyungang | 2018-08-01 |
| Anlotinib in Metastatic HER2 Negative Breast Cancer (NCT04002284) | Peng Yuan | 2018-07-12 |
| Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） (NCT02072031) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2013-12-01 |